Using buprenorphine short-term taper to facilitate early treatment engagement

Brigham, Gregory S.; Amass, Leslie; Winhusen, Theresa; Harrer, Judy M.; Pelt, Alvin

doi:10.1016/j.jsat.2006.09.006

Cited by 24 publications

(18 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Global observations suggested that patients were more comfortable in this study as compared to the prior 3-day patch application study, and self-report and observer ratings of withdrawal support this notion. These data and observations suggest that the longer application of the buprenorphine patch may provide a more effective opioid detoxification, and are in agreement with studies indicating that gradual tapering of low to moderate buprenorphine doses results in a comfortable, effective detoxification (Amass et al 1994;Brigham et al 2007;Gowing et al 2006;Ling et al 2005;Lintzeris et al 2003;Oreskovich et al 2005).…”

Section: Discussionsupporting

confidence: 81%

“…One protocol commonly used in both inpatient and outpatient settings initially escalates doses to 16 mg sublingual before gradually tapering patients to zero over 12-13 days (Amass et al 2004;Brigham et al 2007;Ling et al 2005). A transdermal buprenorphine formulation (i.e., patch) has been developed that may provide several advantages over the currently marketed sublingual formulation, especially for detoxification use.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Opioid detoxification via single 7-day application of a buprenorphine transdermal patch: an open-label evaluation

et al. 2008

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 81%

mentioning

confidence: 99%

Opioid detoxification via single 7-day application of a buprenorphine transdermal patch: an open-label evaluation

et al. 2008

View full text Add to dashboard Cite

show abstract

“…19 Suboxone treatment significantly increased treatment continuation relative to those receiving clonidine taper. The clinicians in this study used a variety of Suboxone dosing strategies, modifying them according to clinical need, without compromising the positive outcomes.…”

mentioning

confidence: 96%

Two-year Experience with Buprenorphine-naloxone (Suboxone) for Maintenance Treatment of Opioid Dependence Within a Private Practice Setting

Finch

Kamien

Amass

2007

Journal of Addiction Medicine

Self Cite

View full text Add to dashboard Cite

Office-based buprenorphine-naloxone (Suboxone) treatment in the United States has significantly improved access to safe and effective opioid-dependence therapy. Little data from physicians' experiences prescribing Suboxone in private offices have been available. This retrospective chart review describes a family practitioner's first 2 years of clinical experience prescribing Suboxone for opioid dependence to 71 patients in a private office. After directly observed rapid office dose induction, Suboxone prescriptions were given monthly after evidence of continued stability. Urine was screened regularly and patients were referred for counseling and other ancillary services. Patients averaged 32 years old, 4.3 years of opioid dependence, and were primarily white (93%) and employed (70%). Fifty-two percent used heroin primarily (most by injection), and 70% had no agonist substitution therapy history. Almost half (47%) paid for their own treatment. Compliance during dose induction was excellent. Suboxone maintenance doses averaged 10 (range, 2-24) mg per day. More than 80% of urine samples were opioid-negative after Suboxone treatment began, although urinalysis did not always include a test for oxycodone. Seventy-five percent had successful outcomes by remaining in Suboxone treatment (43%), tapering successfully (21%), transferring to methadone maintenance (7%), or inpatient treatment (4%). Fifty-eight percent reported receiving counseling. Almost all (85%) paid their fees on time. There were no safety, medication abuse, or diversion issues detected. Overall, office-based Suboxone therapy was easily implemented and the physician considered the experience excellent. Suboxone maintenance was associated with good treatment retention and significantly reduced opioid use, and it is helping to reach patients, including injection drug users, without histories of agonist substitution therapy.

show abstract

“…Considerable work has examined its diffusion in SUD treatment programs and OTPs (Brigham et al, 2007;Ducharme & Abraham, 2008;Ducharme et al, 2007;Friedmann et al, 2010;Gordon et al, 2007;Knudsen et al, 2006Knudsen et al, , 2009Koch et al, 2006;Kovas et al, 2007;Wallack et al, 2010). Several surveys of physicians have examined the nexus between attitudes and prescribing (Arfken et al, 2010;Kissin et al, 2006;Netherland et al, 2009;Reif et al, 2007;Thomas et al, 2008;WESTAT, 2006).…”

mentioning

confidence: 99%

The Supply of Physicians Waivered to Prescribe Buprenorphine for Opioid Use Disorders in the United States: A State-Level Analysis

Knudsen

2015

J. Stud. Alcohol Drugs

View full text Add to dashboard Cite

Using buprenorphine short-term taper to facilitate early treatment engagement

Cited by 24 publications

References 27 publications

Opioid detoxification via single 7-day application of a buprenorphine transdermal patch: an open-label evaluation

Opioid detoxification via single 7-day application of a buprenorphine transdermal patch: an open-label evaluation

Two-year Experience with Buprenorphine-naloxone (Suboxone) for Maintenance Treatment of Opioid Dependence Within a Private Practice Setting

The Supply of Physicians Waivered to Prescribe Buprenorphine for Opioid Use Disorders in the United States: A State-Level Analysis

Contact Info

Product

Resources

About